Form D · Biotechnology
Arrevus, Inc.
Raleigh, NC · CIK 0001707101
Offering snapshot reported Sep 13, 2019 · SEC filing
- Reported sold
- $150K Offering amount: $300K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 30, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 13, 2019 | Initial | $150,000 | No comparison | 1 | SEC filing |
| Aug 3, 2018 | Initial | $300,000 | No comparison | 1 | SEC filing |
| May 25, 2017 | Initial | $999,999 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-348844
Source: Form D, filed Sep 13, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Barry N Garfinkle | Director |
| Robert V House | Director, Executive, Promoter |
| Carl N Kraus | Director, Executive, Promoter |
| Joe N Mcmahon | Director |
| Joe Mc Mahon | Director |
| Robert N Schotzinger | Director |
| Doris N Snow | Promoter |
| Joseph W St. Geme | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2443 Lynn Road, Suite 210
Raleigh, NC, 27612
Raleigh, NC, 27612